Roivant Sciences (ROIV) Competitors

$28.21 -0.34 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$27.86 -0.35 (-1.24%)

As of 07:52 PM Eastern

ROIV vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy Roivant Sciences stock or one of its competitors? MarketBeat compares Roivant Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roivant Sciences include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Roivant Sciences compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Takeda Pharmaceutical has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.53
Roivant Sciences	$13.31M	1,516.90	-$171.98M	-$1.17	N/A

Takeda Pharmaceutical has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

Takeda Pharmaceutical has a net margin of 4.31% compared to Roivant Sciences' net margin of -6,079.94%. Takeda Pharmaceutical's return on equity of 11.07% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Takeda Pharmaceutical had 13 more articles in the media than Roivant Sciences. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 3 mentions for Roivant Sciences. Takeda Pharmaceutical's average media sentiment score of 0.06 beat Roivant Sciences' score of 0.00 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has a consensus target price of $30.55, indicating a potential upside of 8.29%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Takeda Pharmaceutical beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to argenex?

Roivant Sciences (NASDAQ:ROIV) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, argenex had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 5 mentions for argenex and 3 mentions for Roivant Sciences. argenex's average media sentiment score of 0.72 beat Roivant Sciences' score of 0.00 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences currently has a consensus price target of $30.55, indicating a potential upside of 8.29%. argenex has a consensus price target of $1,017.78, indicating a potential upside of 27.58%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$13.31M	1,516.90	-$171.98M	-$1.17	N/A
argenex	$4.25B	11.62	$1.29B	$22.46	35.52

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -6,079.94%. argenex's return on equity of 33.28% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
argenex	31.31%	33.28%	28.16%

Roivant Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Summary

argenex beats Roivant Sciences on 13 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Roivant Sciences (NASDAQ:ROIV) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Teva Pharmaceutical Industries had 15 more articles in the media than Roivant Sciences. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 3 mentions for Roivant Sciences. Teva Pharmaceutical Industries' average media sentiment score of 0.63 beat Roivant Sciences' score of 0.00 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$13.31M	1,516.90	-$171.98M	-$1.17	N/A
Teva Pharmaceutical Industries	$17.26B	2.27	$1.41B	$1.33	25.65

Roivant Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Roivant Sciences' net margin of -6,079.94%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Roivant Sciences presently has a consensus price target of $30.55, suggesting a potential upside of 8.29%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 22.44%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Teva Pharmaceutical Industries beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, BeOne Medicines had 5 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for BeOne Medicines and 3 mentions for Roivant Sciences. BeOne Medicines' average media sentiment score of 0.59 beat Roivant Sciences' score of 0.00 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.10	$286.93M	$4.47	66.45
Roivant Sciences	$13.31M	1,516.90	-$171.98M	-$1.17	N/A

BeOne Medicines presently has a consensus target price of $389.15, suggesting a potential upside of 31.02%. Roivant Sciences has a consensus target price of $30.55, suggesting a potential upside of 8.29%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

BeOne Medicines has a net margin of 8.94% compared to Roivant Sciences' net margin of -6,079.94%. BeOne Medicines' return on equity of 12.06% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Summary

BeOne Medicines beats Roivant Sciences on 13 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Roivant Sciences (NASDAQ:ROIV) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Roivant Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Revolution Medicines	N/A	-83.22%	-59.06%

In the previous week, Revolution Medicines had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Revolution Medicines and 3 mentions for Roivant Sciences. Revolution Medicines' average media sentiment score of 0.53 beat Roivant Sciences' score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Roivant Sciences presently has a consensus price target of $30.55, suggesting a potential upside of 8.29%. Revolution Medicines has a consensus price target of $108.88, suggesting a potential downside of 26.09%. Given Roivant Sciences' higher probable upside, research analysts plainly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

Roivant Sciences has higher revenue and earnings than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$13.31M	1,516.90	-$171.98M	-$1.17	N/A
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A

Summary

Revolution Medicines beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.19B	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-24.11	18.70	20.58	25.11
Price / Sales	1,516.90	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	3.79	6.57	9.68	6.60
Net Income	-$171.98M	$24.30M	$3.55B	$335.71M
7 Day Performance	-4.01%	-3.56%	-2.07%	-2.03%
1 Month Performance	-5.43%	-7.86%	-3.90%	-1.90%
1 Year Performance	160.24%	51.80%	29.39%	27.36%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	1.8899 of 5 stars	$28.21 -1.2%	$30.55 +8.3%	+164.6%	$20.19B	$13.31M	N/A	860
TAK Takeda Pharmaceutical	2.0361 of 5 stars	$16.58 -0.2%	N/A	+17.5%	$52.86B	$28.32B	42.50	47,455	Analyst Downgrade
ARGX argenex	4.6501 of 5 stars	$776.26 -2.9%	$1,017.78 +31.1%	+37.2%	$49.46B	$4.25B	34.56	1,863
TEVA Teva Pharmaceutical Industries	4.5311 of 5 stars	$34.08 -0.6%	$41.78 +22.6%	+101.1%	$39.43B	$17.26B	25.62	33,950	Trending News Insider Trade
ONC BeOne Medicines	4.2669 of 5 stars	$293.09 -0.1%	$389.15 +32.8%	+28.3%	$32.18B	$5.34B	65.57	12,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Roivant Sciences compare to Takeda Pharmaceutical?

Summary

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Roivant Sciences compare to Takeda Pharmaceutical?

Which has preferable earnings and valuation, TAK or ROIV?

Which has more volatility & risk, TAK or ROIV?

Is TAK or ROIV more profitable?

Do institutionals & insiders believe in TAK or ROIV?

Does the media refer more to TAK or ROIV?

Do analysts rate TAK or ROIV?

Summary

How does Roivant Sciences compare to argenex?

Do institutionals and insiders hold more shares of ROIV or ARGX?

Does the media prefer ROIV or ARGX?

Do analysts recommend ROIV or ARGX?

Which has better earnings & valuation, ROIV or ARGX?

Is ROIV or ARGX more profitable?

Which has more volatility & risk, ROIV or ARGX?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Does the media favor ROIV or TEVA?

Which has preferable valuation and earnings, ROIV or TEVA?

Which has more volatility and risk, ROIV or TEVA?

Do institutionals & insiders have more ownership in ROIV or TEVA?

Is ROIV or TEVA more profitable?

Do analysts prefer ROIV or TEVA?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Does the media refer more to ONC or ROIV?

Which has more risk and volatility, ONC or ROIV?

Do institutionals and insiders have more ownership in ONC or ROIV?

Which has better valuation and earnings, ONC or ROIV?

Do analysts rate ONC or ROIV?

Is ONC or ROIV more profitable?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Do institutionals & insiders have more ownership in ROIV or RVMD?

Which has more risk and volatility, ROIV or RVMD?

Is ROIV or RVMD more profitable?

Does the media favor ROIV or RVMD?

Do analysts prefer ROIV or RVMD?

Which has better earnings and valuation, ROIV or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools